Edwards Lifesciences CorporationEWNYSE
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank100
3Y CAGR+4.4%
5Y CAGR+3.8%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+4.4%/yr
vs +6.1%/yr prior
5Y CAGR
+3.8%/yr
Consistent
Acceleration
-1.7pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.2x
Modest growth
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $1.33B | +18.7% |
| 2024 | $1.12B | +7.7% |
| 2023 | $1.04B | -11.1% |
| 2022 | $1.17B | -4.8% |
| 2021 | $1.23B | +11.5% |
| 2020 | $1.10B | -4.9% |
| 2019 | $1.16B | +25.3% |
| 2018 | $922.10M | +4.4% |
| 2017 | $882.90M | +9.6% |
| 2016 | $805.80M | - |